PMID- 25210048
OWN - NLM
STAT- MEDLINE
DCOM- 20141230
LR  - 20181202
IS  - 1479-6805 (Electronic)
IS  - 0022-0795 (Linking)
VI  - 223
IP  - 2
DP  - 2014 Nov
TI  - Thiazolidinedione-induced lipid droplet formation during osteogenic 
      differentiation.
PG  - 119-32
LID - 10.1530/JOE-14-0425 [doi]
AB  - Chronic administration of the insulin-sensitising drugs, thiazolidinediones 
      (TZDs), results in low bone mineral density and 'fatty bones'. This is thought to 
      be due, at least in part, to aberrant differentiation of progenitor mesenchymal 
      stem cells (MSCs) away from osteogenesis towards adipogenesis. This study 
      directly compared the effects of rosiglitazone, pioglitazone, and netoglitazone 
      treatment on osteogenesis and adipogenesis in MSCs derived from subcutaneous (SC) 
      or visceral (PV) white adipose tissue. MSCs were isolated from adipose tissue 
      depots of male Wistar rats and characterised using flow cytometry. The effects of 
      TZD treatment on osteogenic and adipogenic differentiation were assessed 
      histologically (day 14) and by quantitative PCR analysis (Ppargamma2 (Pparg2), Ap2 
      (Fabp4), Adipsin (Adps), Msx2, Collagen I (Col1a1), and Alp) on days 0, 7, and 
      10. Uniquely, lipid droplet formation and mineralisation were found to occur 
      concurrently in response to TZD treatment during osteogenesis. Compared with SC 
      MSCs, PV MSCs were more prone to lipid accumulation under controlled osteogenic 
      and adipogenic differentiation conditions. This study demonstrated that the 
      extent of lipid accumulation is dependent on the nature of the Ppar ligand and 
      that SC and PV MSCs respond differently to in vitro TZD treatment, suggesting 
      that metabolic status can contribute to the adverse effects associated with TZD 
      treatment.
CI  - (c) 2014 Society for Endocrinology.
FAU - van de Vyver, M
AU  - van de Vyver M
AD  - Division of EndocrinologyDepartment of Medicine, Faculty of Medicine and Health 
      Sciences, Stellenbosch University, PO Box 19063, Tygerberg 7505, South Africa.
FAU - Andrag, E
AU  - Andrag E
AD  - Division of EndocrinologyDepartment of Medicine, Faculty of Medicine and Health 
      Sciences, Stellenbosch University, PO Box 19063, Tygerberg 7505, South Africa.
FAU - Cockburn, I L
AU  - Cockburn IL
AD  - Division of EndocrinologyDepartment of Medicine, Faculty of Medicine and Health 
      Sciences, Stellenbosch University, PO Box 19063, Tygerberg 7505, South Africa.
FAU - Ferris, W F
AU  - Ferris WF
AD  - Division of EndocrinologyDepartment of Medicine, Faculty of Medicine and Health 
      Sciences, Stellenbosch University, PO Box 19063, Tygerberg 7505, South Africa 
      wferris@sun.ac.za.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140910
PL  - England
TA  - J Endocrinol
JT  - The Journal of endocrinology
JID - 0375363
RN  - 0 (Thiazolidinediones)
SB  - IM
MH  - Adipocytes/drug effects/physiology
MH  - Adipogenesis/drug effects
MH  - Animals
MH  - Cell Differentiation/drug effects
MH  - Cells, Cultured
MH  - Lipid Droplets/*drug effects/metabolism
MH  - Lipid Metabolism/*drug effects
MH  - Male
MH  - Mesenchymal Stem Cells/*drug effects/physiology
MH  - Osteogenesis/*drug effects
MH  - Rats
MH  - Rats, Wistar
MH  - Thiazolidinediones/*pharmacology
OTO - NOTNLM
OT  - mesenchymal stem cells
OT  - netoglitazone
OT  - pioglitazone
OT  - rosiglitazone
EDAT- 2014/09/12 06:00
MHDA- 2014/12/31 06:00
CRDT- 2014/09/12 06:00
PHST- 2014/09/12 06:00 [entrez]
PHST- 2014/09/12 06:00 [pubmed]
PHST- 2014/12/31 06:00 [medline]
AID - JOE-14-0425 [pii]
AID - 10.1530/JOE-14-0425 [doi]
PST - ppublish
SO  - J Endocrinol. 2014 Nov;223(2):119-32. doi: 10.1530/JOE-14-0425. Epub 2014 Sep 10.